Table 4.

Ingestive behaviors as assessed via Promethion multiplexed phenotyping system

End Point	5L0D + DOCA (n = 9)	2920x + DOCA (n = 9)	P Value
			Diet	Phase	Diet × Phase
Meals per phase, n
Light phase	25.6 ± 3.0	23.6 ± 3.0	0.17	<0.01	0.54
Dark phase	39.9 ± 1.5 a	34.3 ± 3.1 a
Mass consumed per meal, mg
Light phase	65 ± 7	64 ± 6	0.28	0.03	0.10
Dark phase	84 ± 5	66 ± 8
Meal duration, min
Light phase	1.98 ± 0.18	2.43 ± 0.23	0.17	<0.01	0.45
Dark phase	2.51 ± 0.17	2.78 ± 0.19
Intermeal interval, min
Light phase	29.04 ± 3.51	33.11 ± 4.32	0.16	<0.01	0.99
Dark phase	15.01 ± 0.66a	19.19 ± 1.82a
Total food intake within phase, g
Light phase	1.61 ± 0.21	1.36 ± 0.10	<0.01	<0.01	0.07
Dark phase	3.30 ± 0.23a	2.15 ± 0.23a,b
Total fluid intake within phase, mL
Light phase	5.83 ± 0.52	3.14 ± 0.60	<0.01	<0.01	<0.01
Dark phase	12.96 ± 0.80a	6.92 ± 1.06a,b
Total Na intake within phase, mEq
Light phase	0.46 ± 0.07	0.23 ± 0.04	<0.01	<0.01	0.08
Dark phase	0.85 ± 0.09a	0.41 ± 0.08b
Fraction of total Na intake from drink, %
Light phase	33.5 ± 6.2	51.7 ± 8.5	0.03	0.96	0.16
Dark phase	28.6 ± 5.7	56.2 ± 8.0
Total water intake within phase, mL
Light phase	4.65 ± 0.49	2.23 ± 0.42b	<0.01	<0.01	<0.01
Dark phase	11.15 ± 0.63a	5.12 ± 0.78a,b
Total 0.15 M saline intake within phase, mL
Light phase	1.18 ± 0.32	0.91 ± 0.25	0.81	<0.01	0.60
Dark phase	1.81 ± 0.52	1.81 ± 0.53
Pref. for 0.15 M saline within phase, %
Light phase	20.1 ± 5.7	34.8 ± 8.0	0.07	0.08	0.69
Dark phase	13.2 ± 3.5	24.1 ± 4.7

Data presented as means ± SE. Data analyzed by two-way repeated-measures ANOVA. ^aP < 0.05 vs. light phase within treatment group, ^bP < 0.05 vs. 5L0D + DOCA in same phase by Tukey’s multiple comparison procedure. DOCA, deoxycorticosterone acetate.